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Prognostic value of pathological lymph node status and primary tumour regression grading
following neoadjuvant chemotherapy – results from the MRC OE02 oesophageal cancer
trial
Aims: Neoadjuvant chemotherapy (NAC) remains an
important therapeutic option for advanced oesopha-
geal cancer (OC). Pathological tumour regression
grade (TRG) may offer additional information by
directing adjuvant treatment and/or follow-up but its
clinical value remains unclear. We analysed the prog-
nostic value of TRG and associated pathological fac-
tors in OC patients enrolled in the Medical Research
Council (MRC) OE02 trial.
Methods and results: Histopathology was reviewed in
497 resections from OE02 trial participants ran-
domised to surgery (S group; n = 244) or NAC fol-
lowed by surgery [chemotherapy plus surgery (CS)
group; n = 253]. The association between TRG
groups [responders (TRG1–3) versus non-responders
(TRG4–5)], pathological lymph node (LN) status and
overall survival (OS) was analysed. One hundred
and ninety-five of 253 (77%) CS patients were clas-
sified as ‘non-responders’, with a significantly higher
mortality risk compared to responders [hazard ratio
(HR) = 1.53, 95% confidence interval (CI) = 1.05–
2.24, P = 0.026]. OS was significantly better in
patients without LN metastases irrespective of TRG
[non-responders HR = 1.87, 95% CI = 1.33–2.63, P
< 0.001 versus responders HR = 2.21, 95% CI =
1.11–4.10, P = 0.024]. In multivariate analyses, LN
status was the only independent factor predictive of
OS in CS patients (HR = 1.93, 95% CI = 1.42–2.62,
P < 0.001). Exploratory subgroup analyses excluding
radiotherapy-exposed patients (n = 48) showed simi-
lar prognostic outcomes.
Conclusion: Lymph node status post-NAC is the most
important prognostic factor in patients with resect-
able oesophageal cancer, irrespective of TRG.
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Potential clinical implications, e.g. adjuvant treat-
ment or intensified follow-up, reinforce the
importance of LN dissection for staging and
prognostication.
Keywords: oesophageal carcinoma, neoadjuvant chemotherapy, tumour regression grade
Introduction
Multimodal therapy is the standard of care for many
gastrointestinal malignancies.1 For patients with
oesophageal carcinoma (OC), surgery preceded by
neoadjuvant chemotherapy (NAC) or chemoradio-
therapy (NACR) has proven clinical benefit, as
reported in the OE02 [Medical Research Council
(MRC) oesophageal working group] and CROSS
(chemoradiotherapy plus surgery versus surgery
alone for oesophageal or junctional cancer) trials,
respectively.2,3 While geographical variation persists
in the modality of choice4,5 and modest differential
modality benefits are reported,6 NAC/NACR results in
tumour down-staging, increased rate of complete sur-
gical resection and delayed recurrent and metastatic
disease.7 To date, no randomised controlled trial
(RCT) has directly compared neoadjuvant chemother-
apy and neoadjuvant chemoradiation. Until the
results of the Neo-AEGIS (NEOadjuvant Trial in Ade-
nocarcinoma of the oEsophagus and oesophagoGas-
tric Junction International Study)4 trial are published,
NAC remains the principal modality choice in the
United Kingdom. Irrespective of neoadjuvant treat-
ment type, the prognosis of OC patients remains poor,
with a 5-year survival of approximately 15%.8,9 Con-
sequently, it has been suggested that adjuvant
chemotherapy or targeted therapies may be beneficial
to OC patients with high-risk disease.8,10
As described by Mandard et al.11 and others,12
high-risk patients may be identified by pathological
assessment of primary tumour response [tumour
regression grade (TRG)]. A prognostic value of TRG
has been reported in some but not all OC studies.13,14
Additionally, some authors report that primary TRG
is not prognostic in isolation, but only when com-
bined with lymph node (LN) status.15–17
Problematically, most previously reported OC stud-
ies relating to TRG suffer from methodological issues,
including small patient numbers, combined data sets
utilising different disease stages, use of different treat-
ment regimens, use of different TRG systems and
application of different cut-offs to classify ‘responders’
versus ‘non-responders’. Most importantly, previous
studies have not utilised a control arm (e.g. a popula-
tion of patients with the same basic characteristics
treated by surgery alone) to estimate potential
confounding. Thus, it is currently unclear whether
pathological primary tumour TRG and/or other
disease characteristics assessed in the post-NAC resec-
tion specimen can successfully identify high-risk OC
patients,18 the cohort of patients which may benefit
from close follow-up or further adjuvant treatment.
Our own study assessing TRG in patients enrolled
into the Medical Research Council (MRC) Adjuvant
Gastric Infusional Chemotherapy (MAGIC) trial
demonstrated that LN status is the only independent
predictor of survival after NAC in resectable gastro-
oesophageal cancer.7 The majority of these patients,
however, had gastric cancers; only 38 had cancers
located at the gastro-oesophageal junction or lower
oesophagus. Thus, subgroup analyses relating to OC
in the MAGIC trial were methodologically unfeasible.
Given such challenges, we investigated the prog-
nostic value of Mandard TRG, LN status and other
clinicopathological variables in OC patients treated by
either cisplatin combined with 5-fluorouracil (5-FU)
followed by surgery [experimental arm, chemother-
apy plus surgery (CS) patients] or surgery alone (con-
trol arm, S patients) in the Phase III UK MRC OE02
randomised controlled trial of oesophageal cancer.2
Materials and methods
E T H I C S
The study was approved by the South East Research
Ethics Committee, London, UK, REC reference: 07/
H1102/111.
P A T I E N T S
A total of 802 patients with histologically or cytologi-
cally confirmed, locally advanced resectable cancer of
the oesophagus were included in the MRC OE02
trial.19 Patients were randomised to treatment by sur-
gery alone (S patients) or surgery preceded by pre-
operative combination chemotherapy consisting of
two cycles of 5-FU and cisplatin (CS patients).19 In
total, 360 CS patients and 394 S patients proceeded
to surgical resection; 32 CS patients and 16 S
patients did not proceed to surgery for a variety of
reported reasons.19 A small subset of patients from a
single centre was exposed to preoperative
© 2018 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology
2 N Davarzani et al.
radiotherapy (CS patients n = 26, S patients n = 22),
according to local practice.
Original haematoxylin and eosin (H&E)-stained
sections and/or blocks of the formalin-fixed
paraffin-embedded resected specimens were collected
retrospectively from 497 patients (253 CS patients
and 244 S patients), equivalent to 66% of all OE02
trial patients who proceeded to surgery (Figure 1).
S T U D Y D E S I G N
All H&E-stained sections were scanned at 940 mag-
nification using an Aperio XT Scanner (Aperio Tech-
nologies, Vista, CA, USA) and reviewed centrally
using Aperio ImageScope digital slide viewing soft-
ware (version 11.2.0.780). As no central pathology
review was performed at the time of trial accrual,
and TRG assessment was not included in the original
pathology reporting form, histopathological assess-
ment of the resected specimens (including primary
TRG as described by Mandard et al.11) was performed
centrally, with assessors blinded to treatment arm
allocation.
Primary tumours from S and CS patients were
assigned to the TRG/TRG-like categories as follows:
TRG1 (no evidence of residual tumour), TRG2 (fibro-
sis with occasional tumour cells), TRG3 (fibrosis and
tumour cells with a predominance of fibrosis), TRG4
(fibrosis and tumour cells with a predominance of
tumour cells) and TRG5 (tumour with no evidence of
regression). For representative images of histological
features for different TRG categories see Figure S1.
Overall survival (OS) analyses were performed in
CS patients using TRG and LN status (ypN) as indi-
vidual variables. As initial analyses demonstrated
that patients classified as TRG4 or TRG5 had at a
significantly higher mortality risk when compared to
those assigned to TRG1, TRG2 or TRG3 (see Results;
Figure 2), patients with TRG1, TRG2 or TRG3
(TRG1–3) were classified as ‘responders’ and com-
pared to patients with TRG4 or TRG5 (TRG4–5,
‘non-responders’) in subsequent analyses. Further-
more, OS of patients with TRG4–5 without LN
metastasis (non-responders, LN-negative) was com-
pared to OS of patients with TRG4–5 and LN metas-
tasis (non-responders, LN-positive). Similarly, OS of
patients with TRG1–3 without LN metastasis (re-
sponders, LN-negative) was compared to patients
with TRG1–3 and LN metastasis (responders, LN-
positive).


















Patients included in the study
(n = 253)
Patients included in the study
(n = 244)
Figure 1. Study profile, Consolidated Standards of Reporting Trials (CONSORT).
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C L I N I C O P A T H O L O G I C A L D A T A
The central pathology review defined histological
tumour type, grade of differentiation, TRG,11 depth of
invasion (T category) and LN status (N category),
according to the International Union Against Cancer
(UICC) tumour–node–metastasis (TNM) classification,
6th edition.20 Histopathological data that were not
assessable on review of the slides, such as tumour
size, tumour location, number of LNs or resection
margin status, were extracted from the original
pathology report. Clinical outcome data were
extracted from the MRC OE02 clinical trial database.
S T A T I S T I C A L M E T H O D S
Baseline characteristics of CS and S patients were
compared using v2 and Fisher’s exact tests. OS time
was calculated from the date of surgery to the date of
death within the 5-year follow-up period. The surgery
dates were not available for two CS patients, and the
survival time was calculated from a date 9 weeks
after randomisation.
Overall survival was compared using the Kaplan–
Meier method and log-rank test. Patients were
stratified by individual TRG category, TRG group-
ings (responders versus non-responders) and com-
bining TRG groups with LN status (see above). In
order to investigate the relationship between TRG,
LN status and OS, a multivariate survival analysis
was performed using a Cox proportional hazards
model. A P-value of <0.05 was considered
significant.
Results
Slides from 497 resection specimens (66% of OE02
trial patients undergoing surgery) were available for
central pathology review (Figure 1). There were sig-
nificant differences in tumour depth of invasion, LN
status and tumour regression grade/tumour regres-
sion-like changes between CS patients and S patients
(Table 1, P = 0.003, P = 0.003 and P < 0.001,
respectively).
The frequency of the TRG categories in CS patients
(n = 253) was as follows: TRG1: n = 12 (4.8%), TRG2:
n = 10 (4%), TRG3: n = 36 (14.2%), TRG4: n = 96
(37.9%) and TRG5: n = 99 (39.1%) (Table 1). The fre-
quency of ‘tumour regression-like’ changes in S patients
(n = 244) was distributed as follows: TRG1: n = 0 (0%),
TRG2: n = 3 (1.2%), TRG3: n = 15 (6.2%), TRG4:
n = 74 (30.3%) and TRG5: n = 152 (62.3%) (Table 1).
As expected, there were more patients with TRG1–
3 in the CS patient group compared to the S patient
group [CS, n = 58 (76.3%) versus S, n = 18 (23.7%)]
and fewer patients with TRG4–5 in the CS patient
group compared to the S patient group [CS, n = 195
(46.3%) versus S, n = 226 (53.7%)].
Lymph node data were available for 492 patients (CS,
n = 250; S, n = 242). The median (range) number of
retrieved lymph nodes was similar in both treatment
arms [CS, n = 9 (0–67); S, n = 10 (0–80), P = 0.35].
The survival of S patients was similar to CS
patients with TRG4–5 tumours [hazard ratio
(HR) = 1.01; 95% confidence interval (CI) = 0.81–
1.25; P = 0.9, Figure 2]. CS patients with TRG3
tumours demonstrated a trend towards higher mor-
tality risk when compared to CS patients with TRG1-
2 tumours; however, this did not achieve statistical
significance (HR = 1.43, 95% CI = 0.694–2.958,
P = 0.33). Survival analyses of CS patients with
TRG4–5 tumours similarly demonstrated a trend
towards higher mortality risk when compared to CS
group patients with TRG3 tumours, but with a
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Figure 2. Overall survival stratified by tumour regression grade
(TRG) in patients treated by neoadjuvant therapy or surgery alone.
Survival of patients with TRG1, 2 or 3 tumours was similar, and
markedly different from patients with TRG4 or 5 tumours. Survival
of patients treated with surgery alone was similar to that of
patients treated with chemotherapy plus surgery with TRG4 or
5 tumours.
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significant levels (HR = 1.34, 95% CI = 0.858–
2.105, P = 0.196).
The group of CS patients with TRG1–3 tumours (‘re-
sponders’) had a significantly longer OS than the group
with TRG4–5 tumours (‘non-responders) (HR = 1.53,
95% CI = 1.05–2.24, P = 0.026, Figures 2 and 3).
Following the combination of TRG with LN status,
responders without LN metastasis survived signifi-
cantly longer than responders with LN metastasis
(HR = 2.21, 95% CI = 1.11–4.10, P = 0.024). Simi-
larly, non-responders without LN metastasis survived
significantly longer than non-responders with LN
metastasis (HR = 1.87, 95% CI = 1.33–2.63,
P < 0.001, Figure 4). Furthermore, the survival of
responders without LN metastasis was similar to that
of non-responders without LN metastasis (P = 0.12),
and the survival of responders with LN metastasis
was similar to that of non-responders with LN metas-
tasis (P = 0.49).
Multivariate analyses which incorporated TRG and
LN status into the model demonstrated that LN status
was the only independent factor predictive of survival in
CS patients (ypN1; HR = 1.93, 95% CI = 1.42–2.62,
P < 0.001), with assignment to TRG4–5 (‘non-respon-
ders’) not influencing survival significantly (HR = 1.35,
95% CI = 0.92–1.98, P = 0.12, Table 2).








≤65 136 (55.7) 150 (59.3) 0.42
>65 108 (44.3) 103 (40.7)
Gender
Female 65 (26.6) 56 (22.1) 0.24
Male 179 (73.4) 197 (77.9)
Depth of invasion [(y)pT]
T0/Tis 0 (0) 12 (4.7) 0.003
T1 24 (9.8) 25 (9.9)
T2 24 (9.8) 32 (12.7)
T3 190 (77.9) 180 (71.1)
T4 6 (2.5) 4 (1.6)
Lymph node status [(y)pN]
N0 81 (33.2) 117 (46.2) 0.003
N1 163 (66.8) 136 (53.8)
(y)pTNM stage
0 0 (0) 12 (4.8) 0.001
I 19 (7.8) 19 (7.5)
II 77 (31.5) 97 (38.3)




62 (28.4) 63 (26.1) 0.801
Adenocarcinoma 172 (70.5) 171 (71)





1 0 (0) 12 (4.8) <0.001
2 3 (1.2) 10 (4)
3 15 (6.2) 36 (14.2)
4 74 (30.3) 96 (37.9)








TRG and lymph node status (y)pN
TRG1–3 and N0 13 (5.3) 37 (14.6) <0.001
TRG1–3 and N1 5 (2) 21 (8.3)
TRG4–5 and N0 68 (27.9) 80 (31.6)
TRG4–5 and N1 158 (64.8) 115 (45.5)
Resection margin status
Positive 68 (30.6) 70 (30.2) 0.91
Negative 154 (69.4) 162 (69.8)
Tumour location
Lower 153 (62.7) 167 (66) 0.72
Middle 63 (25.8) 61 (24.1)
Upper 28 (11.5) 25 (9.9)
(y)pN, lymph node metastasis; TNM, tumour–node–metastasis.
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Following exclusion of patients exposed to pre-
operative radiotherapy (CS patients n = 26, S patients
n = 22), exploratory subgroup analyses revealed simi-
lar prognostic associations to those from the analysis
of the whole cohort in terms of magnitude and direc-
tion of effect (Figures S2–S5).
Discussion
Following publication in 2002, results from the MRC
OE02 trial changed clinical practice for patients with
locally advanced resectable OC by establishing neoad-
juvant combination chemotherapy followed by sur-
gery as standard of care.19 Tumour regression
grading was, however, not reported in the original
OE02 trial,19 nor in the report of long-term follow-up
for OE02,2 nor in any other large multicentre ran-
domised trial using 5-FU/cisplatin-based neoadjuvant
chemotherapy in OC patients. Thus, to date, the
potential clinical value of TRG in OC patients remains
unclear.7,21,22 Recently, our group has demonstrated,
utilising material from patients with resectable gastric
cancer enrolled into the MRC MAGIC trial, that post-
operative LN status, not TRG, is an independent
predictor of survival following NAC.7 In an effort to
define the clinical value of TRG in a pure OC cohort,
we centrally reviewed (and assigned TRG categories
to) material from 497 patients with resectable OC
enrolled in OE02, a large randomised control trial
that allocated patients either to NAC followed by sur-
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Figure 3. Five-year overall survival stratified by combined tumour
regression grade (TRG) in patients treated with neoadjuvant
chemotherapy plus surgery in the OE02 trial. Patients with TRG1–
3 tumours (responders) survived significantly longer than patients
with TRG4–5 tumours (non-responders) [hazard ratio (HR) = 1.53,
95% confidence interval (CI) = 1.05–2.24, P = 0.026].
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Figure 4. Five-year overall survival stratified by combined tumour
regression grade (TRG) and lymph node status in patients treated
with neoadjuvant chemotherapy plus surgery. Responders (TRG1–3
tumours) without lymph node metastasis (node negative) survived
significantly longer than responders with lymph node metastasis
(node positive) [hazard ratio (HR) = 2.21, 95% confidence interval
(CI) = 1.11–4.10, P = 0.024]. Non-responders (TRG4–5 tumours)
without lymph node metastasis (node negative) survived signifi-
cantly longer than non-responders with lymph node metastasis
(node positive) (HR = 1.87, 95% CI = 1.33–2.63, P < 0.001).
Table 2. Multivariate analysis of factors affecting 5-year
overall survival in patients treated with neoadjuvant
chemotherapy plus surgery (n = 253)
Variable
All patients (n = 253)
HR (95% CI) P-value
TRG1–3
TRG4–5 1.35 (0.92, 1.98) 0.12
ypN0
ypN1 1.93 (1.42, 2.62) <0.001
TRG, tumour regression grade; ypN, lymph node status after che-
motherapy; HR, hazard ratio; CI, confidence interval.
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Overall, our present study shows similar results to
the MAGIC trial of gastric cancer patients.7 The very
low number of patients treated by surgery alone
showing tumour regression-like changes is concor-
dant with MAGIC trial data and supports the accu-
racy of subjective TRG. It is noteworthy that the
Kaplan–Meier overall survival plots for similar TRG
group assignments tracked differently when compar-
ing MAGIC7 and OE02 trial patients (Figure 2). The
reasons for this are unknown but, for methodological
consistency, we utilised a similar approach as used in
the MAGIC trial of merging groups based on similar
survival profiles. Thus, patients classified as TRG1
and TRG2 were grouped as ‘responders’ in MAGIC7
whereas, in the present study, TRG1, 2 and 3 cohorts
were grouped as ‘responders’.
In the present study, patients with lymph node
metastases following NAC treatment had the worst
overall survival, a feature associated with a doubling
of mortality risk when compared to patients without
lymph node metastases. Thus, although the prognos-
tic implication of TRG measurement was demonstra-
ble in univariate analysis, the adverse prognostic
effect of lymph node metastases was retained irrespec-
tive of the perceived response of the primary tumour
to treatment. Our study emphasises the importance of
a complete and thorough lymph node dissection by
the surgeon, as well as comprehensive retrieval of
lymph nodes from the resected specimen by the
pathologist. While TRG grading may offer some infor-
mation on the local response to treatment, the lymph
node status after NAC appears to be more important
in identifying high-risk OC patients and thus may
potentially direct clinical management decisions in
OC patients with high-risk disease for whom adjuvant
therapy and/or intensified follow-up is probably war-
ranted.
Our study has some limitations. This is a retrospec-
tive study based on a 66% subset of OE02 trial
patients who underwent surgery. As the trial was
conducted between 1992 and 1998, and material
collection initiated 20 years following closure of the
trial, material was not obtainable for all patients for
central review. We were, however, able to obtain
TRG values from almost double the number of
patients in comparison to the MAGIC trial study,7
increasing the statistical power for the comparison of
the prognostic importance of TRG and LN status in
subgroup analyses.
The number of lymph nodes could not always be
verified during the central pathology review due to
lack of documentation within the pathology reports,
but is lower than expected in more contemporary
trials reflecting clinical practice at the time of the
trial. For the majority of patients, the number of posi-
tive lymph nodes was not independently verifiable
during central review, as information regarding what
was included in each paraffin block (the blocking list)
was often lacking. Additionally, anatomical location
of the nodes was not recorded in most cases. This lat-
ter aspect is probably important, as recently published
studies suggest that treatment response in lymph
nodes and anatomical location of lymph nodes with
residual disease may be more relevant than primary
tumour TRG when predicting patient prognosis.23–25
Primary analyses also included a small proportion of
patients (CS n = 26, S n = 22), derived from a single
centre, who were subjected to pre-operative radio-
therapy according to local practice. We performed
exploratory subgroup analyses excluding these
patients, demonstrating the retention of the prognos-
tic effects observed in the entire cohort, some with
enhanced prognostic effects (Figures S2–S5). This
subgroup also demonstrated borderline statistical sig-
nificance for TRG as an independent prognostic fac-
tor; however, such an interpretation should be
treated with caution, as these demonstrated good
TRG response but poor survival, thus potentially
skewing statistical interpretation.
Tumour regression grading systems categorise
regressive changes following chemotherapy in order
to provide prognostic information on the basis of
characteristic histopathological changes. As reviewed
recently by Langer and Becker, a variety of systems
are reported for application in gastrointestinal malig-
nancies, each with relative advantages and disadvan-
tages.26 Despite reported disadvantages such as poor
reproducibility, the Mandard system, as utilised for
this study, has demonstable equivalence of repro-
ducibility when compared to other systems, including
the four-tier Becker system, specifically within the
context of oeosphageal malignancies.27
In summary, this study, to the best of our knowl-
edge, represents the first report of the potential prog-
nostic value of centrally reviewed TRG, lymph node
status and other histopathological variables in a ran-
domised trial population of patients with locally
advanced oesophageal cancer treated either by neoad-
juvant combination chemotherapy followed by sur-
gery or surgery alone. We have demonstrated that
pathological LN status is the principal determinant of
OC patient survival after neoadjuvant chemotherapy.
The clinical implications of potential adjuvant treat-
ment or intensified surveillance reinforce the impor-
tance of meticulous lymph node dissection by the
surgeon and the pathologist. Further work is needed
© 2018 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology
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to demonstrate if TRG of intranodal deposits and the
anatomical location of lymph nodes with and without
regression (implying heterogeneity of nodal response)
can provide clinically relevant information beyond
the number of positive lymph nodes alone.
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